BetterLife Pharma files final prospectus for up to US$100 million share and pre-funded warrant offering

Reuters2026/09/11 23:45

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BetterLife Pharma filed a final prospectus for a public offering of up to 555,000,000 common shares or pre-funded warrants.
Gross proceeds targeted at up to USD 100 million, with a minimum raise of USD 80 million.
Pricing set at CAD 0.25 per common share or CAD 0.25 per pre-funded warrant, with a CAD 0.00001 exercise price.
Bloom Burton Securities, Haywood Securities to act as agents; 7% cash commission, 7% broker warrants.
Deal includes a 30-day 15% over-allotment option; closing expected around Sept. 17, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BetterLife Pharma Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202609111945NEWSFILECNPR____20260911_314087_1) on September 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

BetterLife Pharma files final prospectus for up to US$100 million share and pre-funded warrant offering

You may also like

Crypto prices